BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 18367449)

  • 1. Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression.
    Wang H; Ghosh A; Baigude H; Yang CS; Qiu L; Xia X; Zhou H; Rana TM; Xu Z
    J Biol Chem; 2008 Jun; 283(23):15845-52. PubMed ID: 18367449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase.
    Xia XG; Zhou H; Zhou S; Yu Y; Wu R; Xu Z
    J Neurochem; 2005 Jan; 92(2):362-7. PubMed ID: 15663483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis.
    Ding H; Schwarz DS; Keene A; Affar el B; Fenton L; Xia X; Shi Y; Zamore PD; Xu Z
    Aging Cell; 2003 Aug; 2(4):209-17. PubMed ID: 12934714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allele-specific RNAi selectively silences mutant SOD1 and achieves significant therapeutic benefit in vivo.
    Xia X; Zhou H; Huang Y; Xu Z
    Neurobiol Dis; 2006 Sep; 23(3):578-86. PubMed ID: 16857362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [RNAi and neurological disease].
    Yokota T
    Rinsho Shinkeigaku; 2005 Nov; 45(11):973-5. PubMed ID: 16447777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transgenic small interfering RNA halts amyotrophic lateral sclerosis in a mouse model.
    Saito Y; Yokota T; Mitani T; Ito K; Anzai M; Miyagishi M; Taira K; Mizusawa H
    J Biol Chem; 2005 Dec; 280(52):42826-30. PubMed ID: 16221675
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design of functional small interfering RNAs targeting amyotrophic lateral sclerosis-associated mutant alleles.
    Geng CM; Ding HL
    Chin Med J (Engl); 2011 Jan; 124(1):106-10. PubMed ID: 21362317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing strategies for therapy of SOD1-mediated ALS.
    van Zundert B; Brown RH
    Neurosci Lett; 2017 Jan; 636():32-39. PubMed ID: 27507699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. siRNA-based inhibition specific for mutant SOD1 with single nucleotide alternation in familial ALS, compared with ribozyme and DNA enzyme.
    Yokota T; Miyagishi M; Hino T; Matsumura R; Tasinato A; Urushitani M; Rao RV; Takahashi R; Bredesen DE; Taira K; Mizusawa H
    Biochem Biophys Res Commun; 2004 Jan; 314(1):283-91. PubMed ID: 14715277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates.
    Borel F; Gernoux G; Cardozo B; Metterville JP; Toro Cabrera GC; Song L; Su Q; Gao GP; Elmallah MK; Brown RH; Mueller C
    Hum Gene Ther; 2016 Jan; 27(1):19-31. PubMed ID: 26710998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.
    Ralph GS; Radcliffe PA; Day DM; Carthy JM; Leroux MA; Lee DC; Wong LF; Bilsland LG; Greensmith L; Kingsman SM; Mitrophanous KA; Mazarakis ND; Azzouz M
    Nat Med; 2005 Apr; 11(4):429-33. PubMed ID: 15768029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Gene therapy of ALS with RNA interference].
    Yokota T
    Rinsho Shinkeigaku; 2009 Nov; 49(11):821-3. PubMed ID: 20030220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-mismatched siRNAs enhance selective gene silencing of a mutant ALS-causing allele.
    Geng CM; Ding HL
    Acta Pharmacol Sin; 2008 Feb; 29(2):211-6. PubMed ID: 18215350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo application of an RNAi strategy for the selective suppression of a mutant allele.
    Kubodera T; Yamada H; Anzai M; Ohira S; Yokota S; Hirai Y; Mochizuki H; Shimada T; Mitani T; Mizusawa H; Yokota T
    Hum Gene Ther; 2011 Jan; 22(1):27-34. PubMed ID: 20649474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia causes autophagic stress and derangement of metabolic adaptation in a cell model of amyotrophic lateral sclerosis.
    Cimini S; Rizzardini M; Biella G; Cantoni L
    J Neurochem; 2014 May; 129(3):413-25. PubMed ID: 24359187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis.
    Nardo G; Iennaco R; Fusi N; Heath PR; Marino M; Trolese MC; Ferraiuolo L; Lawrence N; Shaw PJ; Bendotti C
    Brain; 2013 Nov; 136(Pt 11):3305-32. PubMed ID: 24065725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stabilization of mutant Cu/Zn superoxide dismutase (SOD1) protein by coexpressed wild SOD1 protein accelerates the disease progression in familial amyotrophic lateral sclerosis mice.
    Fukada K; Nagano S; Satoh M; Tohyama C; Nakanishi T; Shimizu A; Yanagihara T; Sakoda S
    Eur J Neurosci; 2001 Dec; 14(12):2032-6. PubMed ID: 11860498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene transfer demonstrates that muscle is not a primary target for non-cell-autonomous toxicity in familial amyotrophic lateral sclerosis.
    Miller TM; Kim SH; Yamanaka K; Hester M; Umapathi P; Arnson H; Rizo L; Mendell JR; Gage FH; Cleveland DW; Kaspar BK
    Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19546-51. PubMed ID: 17164329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gene therapy of ALS with short interfering RNA].
    Yokota T
    Brain Nerve; 2007 Oct; 59(10):1187-94. PubMed ID: 17969360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis.
    Miller TM; Kaspar BK; Kops GJ; Yamanaka K; Christian LJ; Gage FH; Cleveland DW
    Ann Neurol; 2005 May; 57(5):773-6. PubMed ID: 15852369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.